Add office photos
Employer?
Claim Account for FREE
Wockhardt
3.9
based on 1.4k Reviews
Video summary
Company Overview
Associated Companies
Company Locations
Working at Wockhardt
Company Summary
Wockhardt is a global pharmaceutical entity focused on affordable healthcare solutions, including medicines, vaccines, and specialty hospital services.
Overall Rating
3.9/5
based on 1.4k reviews
On-Par with
industry average
Highly rated for
Work-life balance, Company culture, Skill development
Critically rated for
Promotions
Work Policy
Work from office
85% employees reported
Monday to Saturday
51% employees reported
Flexible timing
53% employees reported
Within city
39% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
114 employees reported
Health insurance
110 employees reported
Free meal
88 employees reported
Office cab/shuttle
65 employees reported
View all benefits
About Wockhardt
Founded in1999 (26 yrs old)
India Employee Count5k-10k
Global Employee Count5k-10k
India HeadquartersMumbai, Maharashtra, India
Office Locations
--
Websitewockhardt.com
Primary Industry
Other Industries
--
Are you managing Wockhardt's employer brand? To edit company information,
claim this page for free
View in video summary
Wockhardt is a global pharmaceutical and biotechnology organisation, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals. Wockhardt is a true Indian Multi-National Company with a multi-ethnic workforce of 8600 Wockhardt Associates from 21 different nationalities globally. It has 3 research centres and 12 manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines.
Managing your company's employer brand?
Claim this Company Page for FREE
Brands of Wockhardt
Wockhardt Foundation
3.6
• 93 reviews
Wockhardt Ratings
based on 1.4k reviews
Overall Rating
3.9/5
How AmbitionBox ratings work?
5
710
4
366
3
159
2
77
1
102
Category Ratings
4.0
Work-life balance
3.9
Company culture
3.8
Skill development
3.7
Work satisfaction
3.6
Job security
3.4
Salary
3.0
Promotions
Wockhardt is rated 3.9 out of 5 stars on AmbitionBox, based on 1.4k company reviews.This rating reflects an average employee experience, indicating moderate satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Wockhardt
based on 1.3k reviews
3.5
Rated by 121 Women
Rated 3.6 for Work-life balance and 3.5 for Skill development
3.9
Rated by 1.2k Men
Rated 4.0 for Work-life balance and 3.9 for Company culture
Work Policy at Wockhardt
based on 84 reviews in last 6 months
Work from office
85%
Hybrid
13%
Permanent work from home
2%
Wockhardt Reviews
Top mentions in Wockhardt Reviews
+ 5 more
Compare Wockhardt with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 3.9/5 based on 1.4k reviews | 4.0/5 based on 7.1k reviews | 4.1/5 based on 6.4k reviews | 4.1/5 based on 7.2k reviews |
Highly Rated for | Work-life balance Company culture Skill development | Skill development Company culture Work-life balance | Skill development Company culture Work-life balance | Skill development Salary Work-life balance |
Critically Rated for | Promotions | Promotions | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 85% employees reported | Work from office 74% employees reported | Work from office 86% employees reported | Work from office 72% employees reported |
Rating by Women Employees | 3.5 Good rated by 121 women | 4.0 Good rated by 801 women | 4.0 Good rated by 382 women | 4.0 Good rated by 726 women |
Rating by Men Employees | 3.9 Good rated by 1.2k men | 4.1 Good rated by 5.9k men | 4.1 Good rated by 5.7k men | 4.1 Good rated by 6.1k men |
Job security | 3.6 Good | 3.5 Good | 3.7 Good | 3.7 Good |
View more
Wockhardt Salaries
Wockhardt salaries have received with an average score of 3.4 out of 5 by 1.4k employees.
Key Account Manager
(142 salaries)
Unlock
₹2.6 L/yr - ₹9 L/yr
Research Scientist
(127 salaries)
Unlock
₹4.9 L/yr - ₹16.4 L/yr
Senior Officer
(103 salaries)
Unlock
₹2 L/yr - ₹6.8 L/yr
Territory Manager
(94 salaries)
Unlock
₹2.1 L/yr - ₹5.2 L/yr
Junior Executive
(84 salaries)
Unlock
₹3.1 L/yr - ₹7 L/yr
Regional Manager
(82 salaries)
Unlock
₹4.2 L/yr - ₹11 L/yr
Senior Research Associate
(71 salaries)
Unlock
₹2.9 L/yr - ₹8 L/yr
Research Associate
(54 salaries)
Unlock
₹2.8 L/yr - ₹5.5 L/yr
Senior Research Scientist
(50 salaries)
Unlock
₹7 L/yr - ₹20.1 L/yr
Zonal Sales Manager
(48 salaries)
Unlock
₹8 L/yr - ₹18 L/yr
Wockhardt Interview Questions
Interview questions by designation
Top Wockhardt interview questions and answers
Get interview-ready with top interview questions
Wockhardt Jobs
Popular Designations Wockhardt Hires for
Medical Representative
Create job alerts
Scientific Manager
Create job alerts
Product Manager
Create job alerts
Senior Business Development Manager
Create job alerts
Deputy General Manager
Create job alerts
Current Openings
Wockhardt News
View all
Tech Query: What is the outlook for Samvardhana Motherson International, Arrow Greentech, Wockhardt, Jubilant Foodworks?
- Samvardhana Motherson International: The stock is in a downtrend with a potential support zone at ₹100-90. A fresh rally can occur after this fall, taking the stock up to ₹250 in the next couple of years.
- Arrow Greentech: The stock is currently in a correction phase within a broader uptrend. A potential support zone at ₹480-470 can lead to a rise in the stock price up to ₹1,100 over the next three-four quarters.
- Wockhardt: The stock is oscillating in a range of ₹1,100-1,700 and shows the possibility of a double-top pattern formation. A break below ₹1,050 can lead to a further decline to ₹950 or ₹800. It would need to breach ₹1,700 to regain bullish momentum.
- Jubilant Foodworks: The long-term outlook for Jubilant Foodworks is bullish, with a potential rise to ₹880 in the coming months and a target of ₹1,200-1,300 over the next two-three years. Accumulate shares on dips at ₹590 and ₹540.
HinduBusinessLine | 12 Apr, 2025
Wockhardt to exit residual US generics business for “commercial reasons”
- Wockhardt, the Mumbai-based drugmaker, has decided to exit its residual US generics business for commercial reasons.
- The decision is not related to the tariffs announced by US President Trump on pharmaceuticals.
- Wockhardt's US business accounted for ₹25 crore in the third quarter of FY25 and ₹85 crore for the nine months FY25.
- The company had already closed its manufacturing facility in Illinois in 2022 as part of cost optimization measures.
HinduBusinessLine | 7 Apr, 2025
Buy, Sell Or Hold: Trent, L&T, Titan, Infosys, Tata Motors, Bajaj Finserv, Bharat Forge — Ask Profit
- Analysts provide insights on stocks including Trent, L&T, Titan, Infosys, Tata Motors, Bajaj Finserv, Bharat Forge, Wockhardt, and Suzlon Energy.
- Trent: Chokkalingam suggests holding due to potential market correction and competition from online stores.
- L&T: Ail advises holding, anticipating a bounceback close to Rs 3,450–3,500 after sustaining above Rs 31,000.
- Titan: Jain recommends buying, with the company being a preferred choice for gold stocks and near monthly support levels.
- Bajaj Finserv: Ail suggests buying, expecting the stock to reach close to Rs 22,000 levels and a current marginally down market.
- Infosys: Chokkalingam advises buying for medium to long-term, considering the expected outperformance of IT sector in the next 1-2 years.
- Wockhardt: Chokkalingam suggests selling and buying FDC Ltd. instead, citing ongoing losses and possible industry challenges.
- Bharat Forge: Chokkalingam suggests holding due to tariff war impact and preference for domestic demand-driven sectors despite a potential bounce back.
- Tata Motors: Chokkalingam advises holding for the long term, despite stagnant business growth, suggesting a potential comeback in 1-2 years.
- Suzlon Energy: Ojha advises holding for further potential upside, with expectations of reaching Rs 72–75 zone in one year. Jain also recommends holding, expecting a recovery near Rs 61–63 levels.
- Investors are advised to consult their financial advisors before making any investment decisions.
Bloomberg Quint | 7 Apr, 2025
Wockhardt’s novel antibiotic gets CDSCO approval
- Wockhardt's novel antibiotic, Miqnaf, has received approval from the Central Drugs Standard Control Organization (CDSCO).
- Miqnaf is an ultra-short course, once-a-day, 3-day treatment for Community-Acquired Bacterial Pneumonia (CABP) in adults.
- It covers a wide range of community respiratory pathogens, including those resistant to azithromycin and amoxicillin/clavulanate.
- Wockhardt plans to launch Miqnaf in the local market in a few months.
HinduBusinessLine | 3 Jan, 2025
One In Four IPOs Joined Billion-Dollar Valuation Club In 2024; Total Adds Hit Triple Digits
- Over 100 companies joined the billion-dollar valuation club in 2024, with the largest valuations belonging to newly listed companies.
- Hyundai Motor India, Swiggy, and Bajaj Housing Finance were among the largest newly listed companies with valuations over Rs 1 lakh crore.
- KFin Technologies Ltd. has the largest valuation among non-new offerings, followed by PG Electroplast Ltd. and Wockhardt Ltd.
- LS Industries Ltd. topped the list of companies that grew the most during the year, crossing a $1 billion valuation.
Bloomberg Quint | 31 Dec, 2024
Wockhardt’s Zaynich gives new hope to cancer patient with successful liver transplant
- Zidebactam/Cefepime (WCK 5222) facilitated a successful liver transplant for a cancer patient at Houston Methodist Hospital, Texas.
- The drug helped clear a chronic bile duct infection and led to the patient's discharge from the hospital.
- The patient had failed to respond to other antibiotics before using Zidebactam/Cefepime under compassionate use.
- 45 patients have benefited from the compassionate use of Zidebactam/Cefepime, which is nearing completion of its Phase III study.
HinduBusinessLine | 16 Dec, 2024
Wockhardt Share Price At Life High As Patent Drug Aids US Patient With Transplant Surgery
- Shares of Wockhardt Ltd. hit a life high as its proprietary antibiotic, ZaynichTM, helped a US patient undergo a successful liver transplant and resume chemotherapy.
- The patient, diagnosed with bile duct cancer, developed severe complications that did not respond to advanced antibiotics. Zaynich was used under compassionate use and eradicated the infections within 15 days.
- The drug's innovative β-lactam enhancer mechanism neutralised resistance mechanisms, marking a significant milestone in infection management.
- Wockhardt stock rose as much as 10% during the day to Rs 1,536.60 apiece on the NSE.
Bloomberg Quint | 16 Dec, 2024
Indigenous development of Nafithromycin marks key milestone in AMR battle: Government
- Indigenous development of Nafithromycin, also known as 'Miqnaf,' marks a key milestone in the battle against Antimicrobial Resistance (AMR), according to the Indian government.
- Nafithromycin is a new antibiotic developed by Wockhardt with support from BIRAC.
- It targets Community-Acquired Bacterial Pneumonia (CABP) caused by drug-resistant bacteria.
- The antibiotic is ten times more effective than current treatments and offers a three-day treatment regimen, shortening recovery time and improving patient outcomes.
HinduBusinessLine | 6 Dec, 2024
Stock Recommendations Today: Experts' Views On Canara Bank, Oil India, Tata Steel, Ugro Capital, Wockhardt
- The view is positive on Tata Steel Ltd. at the current level.
- Astha Jain recommends Canara Bank as a good 'buy' with a target of Rs 120-130.
- Astha Jain suggests a buy on Ugro Capital with a price target of Rs 280-290.
- Hem Securities recommends holding on to Wockhardt with an initial price target of Rs 1,500-1,550.
Bloomberg Quint | 3 Dec, 2024
‘Rs 8 Crore Assistance’: Govt Fact Checks Claims On Nafithromycin Antibiotic
- The Department of Biotechnology clarified that Wockhardt invested Rs 500 crore in developing Nafithromycin, with Rs 8 crore financial support from BIRAC for trials.
- The government refuted claims circulating on social media regarding India's first indigenously developed antibiotic, Nafithromycin.
- Debunking the fake news, the Department of Biotechnology stated that the antibiotic has been developed by Wockhardt at an investment of Rs 500 crore, with Rs 8 crore financial assistance from BIRAC.
- Nafithromycin, marketed as Miqnaf, is designed to address antimicrobial resistance and treat Community-Acquired Bacterial Pneumonia.
Bloomberg Quint | 22 Nov, 2024
Powered by
Wockhardt Subsidiaries
PINEWOOD HEALTHCARE
5.0
• 1 review
Report error
Compare Wockhardt with
Zydus Lifesciences
4.1
Sun Pharmaceutical Industries
4.0
Aurobindo Pharma
4.0
Hetero
3.9
Viatris
4.1
Alembic Pharmaceuticals
4.0
Abbott
4.1
Ipca Laboratories
3.9
Glenmark Pharmaceuticals
3.9
Alkem Laboratories
3.9
Torrent Pharmaceuticals
3.9
Mankind Pharma
3.9
MSN Laboratories
3.7
Ajanta Pharma
4.0
Akums Drugs & Pharmaceuticals Limited
4.4
Cadila Pharmaceuticals
3.4
GlaxoSmithKline Pharmaceuticals
4.1
Pfizer
3.9
Laurus Labs
4.2
Novartis
4.1
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Companies Similar to Wockhardt
Cipla
Manufacturing, Pharma
4.1
• 7.2k reviews
Dr. Reddy's
Clinical Research, Pharma
4.0
• 7.1k reviews
Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.1
• 6.4k reviews
Zydus Lifesciences
Biotech & Life sciences, Pharma
4.1
• 6.2k reviews
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.0
• 6.1k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 5k reviews
Intas Pharmaceuticals
Biotech & Life sciences, Pharma
4.1
• 3.6k reviews
Hetero
Healthcare / Pharma, Clinical Research, Healthcare, Pharma
3.9
• 3.5k reviews
Viatris
Manufacturing, Pharma
4.1
• 3.3k reviews
Alembic Pharmaceuticals
Real Estate, Engineering & Construction, Biotechnology, Pharma
4.0
• 3.2k reviews
Abbott
Healthcare / Pharma, Media & Entertainment / Publishing, Pharma
4.1
• 3.2k reviews
Ipca Laboratories
Pharma
3.9
• 3.1k reviews
Wockhardt FAQs
When was Wockhardt founded?
Wockhardt was founded in 1999. The company has been operating for 26 years primarily in the Pharma sector.
Where is the Wockhardt headquarters located?
Wockhardt is headquartered in Mumbai, Maharashtra.
How many employees does Wockhardt have in India?
Wockhardt currently has more than 6,900+ employees in India. Research & Development department appears to have the highest employee count in Wockhardt based on the number of reviews submitted on AmbitionBox.
Does Wockhardt have good work-life balance?
Wockhardt has a work-life balance rating of 4.0 out of 5 based on 1,400+ employee reviews on AmbitionBox. 76% employees rated Wockhardt 4 or above on work-life balance. This rating reflects the company's efforts to help employees maintain a healthy balance between their personal and professional lives. We encourage you to read Wockhardt work-life balance reviews for more details
Is Wockhardt good for career growth?
Career growth at Wockhardt is rated as moderate, with a promotions and appraisal rating of 3.0. 24% employees rated Wockhardt 3 or below, while 76% employees rated it 4 or above on promotions/appraisal. This rating suggests that while some employees view growth opportunities favorably, there is scope for improvement based on employee feedback. We recommend reading Wockhardt promotions/appraisals reviews for more detailed insights.
What are the pros and cons of working in Wockhardt?
Working at Wockhardt comes with several advantages and disadvantages. It is highly rated for work life balance, company culture and skill development. However, it is poorly rated for promotions / appraisal, based on 1,400+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
75 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
